A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Clinical trial NCT06626919 · RECRUITING

Trial details

NCT number: NCT06626919
Sponsor: Arcellx, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Muscular Diseases Neuromuscular Manifestations Autoimmune Autoimmune Diseases Autoimmune Diseases of the Nervous System Myasthenia Gravis Muscle Weakness

Start date: 2025-04-30
Primary completion: 2027-03-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.